Meeting
2024 ASCO Annual Meeting
Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.
Authors
Cristina Larrosa
Hospital Sant Joan de Deu, Barcelona, Spain
Cristina Larrosa , Margarida Simao Rafael , Juan Pablo Muñoz , Maite Gorostegui , Alicia Castaneda Heredia , Moira Garraus , Jaume Mora
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 10037)
DOI
10.1200/JCO.2024.42.16_suppl.10037
Abstract #
10037
Poster Bd #
404
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2017 ASCO Annual Meeting
A pilot trial of irinotecan, temozolomide and bevacizumab (ITB) for treatment of newly diagnosed patients with desmoplastic small round cell tumor (DSRCT).
First Author: Heather D. Magnan
Poster
2023 ASCO Annual Meeting
Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C).
First Author: Emily Gustava Greengard
Poster
2023 ASCO Annual Meeting
Personalized therapy for head and neck squamous carcinoma (HNSCC) utilizing tissue proteomics profiling.
First Author: Sheeno P. Thyparambil